Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
mBio 15 (11), e0231024
What the research says Recent results from a late-stage clinical trial called REDEFINE 1, which included 3,417 people with overweight or obesity (without type 2 diabetes), showed that CagriSema led to almost 23% weight loss, surpassing cagrilintide and semaglutide alone
Convalescent plasma for COVID-19
A fund may be a constituent of one or more indices or models which could greatly affect a fund's trading activity, size and volatility
US$ 22.33
US$ 21.62
US$ 23.91
US$ 23.01
US$ 20.86
US$ 22.74
US$ 20.78
US$ 25.07
US$ 25.92
